AstraZeneca shows cardiovascular safety for roxadustatAstraZeneca has announced that pooled analyses of the phase III trials for its kidney disease drug roxadustat confirm Share XAstraZeneca shows cardiovascular safety for roxadustathttps://pharmaphorum.com/news/astrazeneca-shows-cardiovascular-safety-for-roxadustat/
Spain’s Sanifit chasing calcium disorder blockbusterSpanish biotech Sanifit is targeting calcification disorders, and says it could have a potential multi-billion dollar treatment in Share XSpain’s Sanifit chasing calcium disorder blockbusterhttps://pharmaphorum.com/news/spains-sanifit-chasing-calcium-disorder-blockbuster/
NICE rejects Opdivo in advanced kidney cancerNICE said survival benefits are unclear. Share XNICE rejects Opdivo in advanced kidney cancerhttps://pharmaphorum.com/news/nice-rejects-bms-opdivo-advanced-kidney-cancer/